Literature DB >> 17646740

Antagonistic drug combinations that select against drug resistance: from bacteria to cancer.

Mikhail V Blagosklonny1.   

Abstract

Any drug selects for drug resistance. But super-antagonistic drug combinations can select for drug sensitivity. This has important application not only for antibacterial therapy but also for cancer therapy: to control cancer with lesser side effects and to eliminate drug-resistant cancer cells, while sparing sensitive normal cells.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17646740     DOI： 10.4161/cbt.6.7.4340

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  13 in total

1.  Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.

Authors:  Shuya Yano; Kiyoto Takehara; Ming Zhao; Yuying Tan; Qinghong Han; Shukuan Li; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2016-05-06       Impact factor: 4.534

2.  Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness.

Authors:  Shuya Yano; Yong Zhang; Shinji Miwa; Yasunori Tome; Yukihiko Hiroshima; Fuminari Uehara; Mako Yamamoto; Atsushi Suetsugu; Hiroyuki Kishimoto; Hiroshi Tazawa; Ming Zhao; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2014-05-08       Impact factor: 4.534

3.  Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy.

Authors:  Shuya Yano; Yong Zhang; Ming Zhao; Yukihiko Hiroshima; Shinji Miwa; Fuminari Uehara; Hiroyuki Kishimoto; Hiroshi Tazawa; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

4.  Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-06

5.  NCI's provocative questions on cancer: some answers to ignite discussion.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2011-12

6.  Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials.

Authors:  Miguel López-Lázaro
Journal:  Oncoscience       Date:  2015-02-20

7.  Traditional Chinese medicine herbal mixture LQ arrests FUCCI-expressing HeLa cells in G₀/G₁ phase in 2D plastic, 2.5D Matrigel, and 3D Gelfoam culture visualized with FUCCI imaging.

Authors:  Lei Zhang; Chengyu Wu; Michael Bouvet; Shuya Yano; Robert M Hoffman
Journal:  Oncotarget       Date:  2015-03-10

8.  Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity.

Authors:  Shuya Yano; Shukuan Li; Qinghong Han; Yuying Tan; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Oncotarget       Date:  2014-09-30

9.  Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.

Authors:  Xiao-Kun Wang; Kenneth Kin Wah To; Li-Yan Huang; Jing-Hong Xu; Ke Yang; Fang Wang; Zhen-Cong Huang; Sheng Ye; Li-Wu Fu
Journal:  Oncotarget       Date:  2014-12-15

10.  Selective anti-cancer agents as anti-aging drugs.

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2013-11-27       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.